Skip to content
Magazine
Sunday, August 3, 2025
SUBSCRIBE
  • About Us
  • Belgium News
    • Belgium Police News
    • Brussels News
  • EU Institutions News
    • European Commission News
    • European Parliament News
    • European Council News
  • Europe News
  • World News
  • Belgium Business News
  • Culture and Society News
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
  • About Us
  • Belgium News
    • Belgium Police News
    • Brussels News
  • EU Institutions News
    • European Commission News
    • European Parliament News
    • European Council News
  • Europe News
  • World News
  • Belgium Business News
  • Culture and Society News
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
SUBSCRIBE

Italian firm ReiThera in early talks to supply corona vaccine to EU

Shiva Singh by Shiva Singh
22 September 2020
in Europe News, Features

ReiThera, the Italian biotech company, is in early talks to supply the EU with the coronavirus vaccine it is currently developing, according to unnamed sources cited by Reuters. Reportedly, negotiations are in the initial stages and the outcome remains unclear.

The talks represent the latest attempt by the EU to secure a vaccine, with Brussels seeking to raise more money in order to secure adequate supplies of a vaccine and assuage concerns that demand could exceed supply in 2021. ReiThera is developing a vaccine in cooperation with Germany’s Leukocare and Belgium’s Univercells. 

This latest endeavour brings the number of vaccine makers the European Commission (EC) is negotiating with to a total of seven. The EC has deals with the French company Sanofi to buy up to 300 million doses and with the UK’s AstraZeneca for up to 400 million doses.

The vaccine being developed by ReiThera draws on the same technology used in the AstraZeneca and Johnson & Johnson vaccines. It is currently being tested on 90 volunteers in Italy as part of a phase I study. Results are expected by the end of 2020. Depending on the outcome, the next phase will start in late 2020 in countries with high infection rates.

Keeping in mind the negative effects of lockdowns in the EU, member states are desperate to avoid imposing severe measures yet again, DW reports. France is responding to the recent upsurge of the virus by tightening restrictions in hotspots including Paris, Marseille, Toulouse, Nice and Bordeaux in its efforts not to resort to a second nationwide lockdown. In Spain, Madrid imposed strict restrictions on Monday, while Germany and the UK are considering the possibility of localized lockdowns, depending on the outcome of epidemiologic trends.

According to the World Health Organisation (WHO), the number of new cases per day in Europe stands between 40,000 and 50,000.

SOURCE

Tweets by EU_Commission
Tweets by AstraZeneca
Tweets by JNJNews
Tweets by WHO

Related News:

  • EU Special COVID-19: EU-wide corona testing and vaccine supply on the EC agenda
  • COVID vaccine ready early next year, says UK vaccine chief
  • Greece and Turkey to resume talks by early March
  • Commission reaches deal with Novanax for COVID-19 vaccine supply
Tags: EUItalyVaccine
Next Post

French Iliad's shares drop following bid for Polish Play

Latest post

EU-elections-UK

EU elections: UK looks on from the “outside”

1 year ago
Galeries-Royales-Saint-Hubert

What Makes Galeries Royales Saint-Hubert an “Institution”?

1 year ago

Most Read

    Follow Brussels Morning
    Facebook Twitter Youtube Linkedin

    Browse Important News

    Belgium News
    Brussels News
    Culture and Society News
    Economy News
    EU Institutions News
    European Commission News
    European Council News
    European Parliament News
    Europe News
    Health And Fitness News
    Southeast Europe News
    Sustainable Perspective
    World News
    Diplomacy News
    US Elections News

    About Us

    Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

    More Info

    • About Us
    • Advertise With Us
    • Contact Us
    • Cookies Policy

    Join Our Newsletter

    Brussels Morning Newspaper – All Rights Reserved © 2024

    No Result
    View All Result
    • Home
    • About Us
    • Belgium News
      • Belgium Police News
      • Brussels News
    • Brussels Bubble
      • European Parliament News
      • European Commission News
      • European Council News
    • Wider Europe
      • Member States
    • World News
    • Business & Society
    • Europe With Transparency
    • Culture & Society
    • Policy Talks
      • Place de la Bourse
      • The Macro-Economist
      • Sustainable Perspective
      • Ambassador’s Corner
      • The American Angle
      • Southeast Europe
    • Print Magazine

    Brussels Morning Newspaper - All Rights Reserved © 2020

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Cookie settingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT